Web Exclusives

During active chemotherapy treatment, adopting an aerobic exercise program may reduce cancer-related fatigue. Read More ›

Patient outcomes could be improved through targeted education for oncology nurses focused on managing treatment-related adverse events. Read More ›

A new landmark study, MONALEESA-3, demonstrates extended overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Read More ›

Nurses play a significant role in addressing the challenges of monitoring nutrition in cancer patients. Read More ›

Personalized, risk-adapted breast cancer screening may establish a new category of screening appropriate for low-risk patients for whom less-intensive screening is sufficient. Read More ›

In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy. Read More ›

Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab. Read More ›

Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab. Read More ›

Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma. Read More ›

Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer. Read More ›

Page 10 of 61

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: